Your browser doesn't support javascript.
Hyperbaric oxygen therapy as a supportive therapy for COVID-19 patients: a narrative review.
Allam, N M; Eladl, H M; Eid, M M.
  • Allam NM; Department of Physical Therapy and Health Rehabilitation, College of Applied Medical Science, Jouf University, Jouf, Saudi Arabia. hd_mos@yahoo.com.
Eur Rev Med Pharmacol Sci ; 26(15): 5618-5623, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1988909
ABSTRACT
The Coronavirus illness 2019 (COVID-19) was first observed to induce fever, dry cough, pneumonia, and dyspnea in the lower respiratory tract. Atypical manifestations, including digestive problems and cardiac symptoms, were also observed. The rate of mortality in the older population is greater than in the younger group, as well as in individuals suffering from comorbidities. Oxygen supplementation through a facemask, non-invasive ventilation, mechanical ventilation, and extracorporeal membrane oxygenation ECMO are some of the available supportive techniques. Hyperbaric oxygen treatment (HBOT) is thought to boost tissue oxygenation by increasing plasma soluble oxygen levels. HBOT also reduces inflammatory responses in COVID-19 patients, minimizing the negative impacts of the cytokine storm. Because the existing data on the efficacy of HBOT in COVID-19 patients is limited, the purpose of this article is to review the possible mechanisms of HBO, as well as data available on potential advantages, side effects and uses in the treatment of COVID-19 patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / COVID-19 / Hyperbaric Oxygenation Type of study: Reviews Limits: Humans Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2022 Document Type: Article Affiliation country: Eurrev_202208_29435

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / COVID-19 / Hyperbaric Oxygenation Type of study: Reviews Limits: Humans Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2022 Document Type: Article Affiliation country: Eurrev_202208_29435